Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK6
REST API REST API
Homo sapiens
MAPK6 is differentially expressed in 288 experiments: 114 organism parts: bone marrow, cerebellum, ... (112 more);, 161 disease states: normal, prostate carcinoma, ... (159 more);, 95 cell types 323 cell lines 47 compound treatments and 72 other conditions.
Synonyms ERK3, PRKM6, HsT17250, p97MAPK
Orthologs FUS3 (Saccharomyces cerevisiae)   KSS1 (Saccharomyces cerevisiae)   MK06_CHICK (Gallus gallus)   Q4H3L4_CIOIN (Ciona intestinalis)   mapk6 (Danio rerio)   MAPK6 (Bos taurus)   Mapk6 (Mus musculus)   Mapk6 (Rattus norvegicus)   mapk6 (Xenopus laevis)   MAPK6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, protein tyrosine kinase activity, MAP kinase activity, ATP binding, cell cycle, nucleotide binding, protein serine/threonine kinase activity, signal transduction, protein kinase activity, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Erk_3_4_MAPK, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q16659
Search EB-eye ENSG00000069956
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
LNCaP
2
E-GEOD-14464, E-GEOD-14990
BT-474
2
E-GEOD-5823, E-GEOD-3529
HL-60
2
E-GEOD-24147, E-GEOD-5258
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
317 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-750, E-GEOD-4219, E-GEOD-20677, E-TABM-34, ... (48 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
SVG-A
1
E-GEOD-7819
LCC
1
E-GEOD-19188
mesothelial cells
1
E-GEOD-21750
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (50 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-GEOD-96, E-MEXP-1327, E-MTAB-62, E-MEXP-2034
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
chronic myelogenous leukemia K562
2
E-AFMX-5, E-TABM-145
colon carcinoma
2
E-MTAB-37, E-MTAB-62
bone tumor
1
E-MTAB-62
155 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-TABM-782, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
2
8
E-MEXP-1601, E-GEOD-5824, E-TABM-782, E-GEOD-412, E-GEOD-2803, ... (10 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
NaOH
1
E-MEXP-2590
sapphyrin PCI-2050
1
E-GEOD-6400
1mM GDC-0941
1
1
E-GEOD-20719
granulocyte-colony stimulating factor
1
E-GEOD-7400
41 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-GEOD-4006 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-MEXP-2657, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-10433, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-6802, ... (6 experiments)

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-7114 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.378 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM